Avance Clinical Appoints Liahna Toy to Lead Global Early Phase Center of Excellence

“Early phase development sets the trajectory for a program,” said Toy. “Biotechs need a CRO partner that understands both scientific complexity and capital efficiency. Our teams are focused on de-risking programs, accelerating timelines, and delivering globally accepted data that sponsors can use with confidence.”

The company’s Early Phase Center of Excellence is delivered through a globally integrated model across Australia, New Zealand, the United States, the United Kingdom, South Korea, Taiwan and India, providing consistent governance, and regional execution expertise. This gives sponsors greater flexibility in where they run studies while maintaining continuity in oversight, quality and delivery.

The model is underpinned by the Australian Advantage, including rapid start-up under the Clinical Trial Notification (CTN) scheme, globally accepted data to support FDA and EMA pathways, and cost efficiencies through Australia’s R&D Tax Incentive. Together, these factors help sponsors start smart, preserve capital and progress with confidence as programs expand internationally.

“For global biotechs, this creates a practical and cost-efficient pathway to advance assets without compromising scientific rigor,” added Toy. “Australia’s multicultural population support targeted recruitment across priority therapeutic areas, while maintaining a high bar for data quality and operational execution.”

Avance Clinical will be attending BIO-Europe Spring 2026, March 23–25 in Lisbon, Portugal. Biotech leaders advancing Phase I programs are invited to schedule partnering meetings with Avance Clinical’s team, via the BIO-Europe Spring partnering platform.